SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas is trending due to its strategic partnership with Palantir and World View to develop AI-enabled multi-domain intelligence and defense systems, a move seen as highly transformative by the community alongside recent defense tech acquisitions. While many investors are bullish on the company's long-term potential and anticipate a short squeeze, others are expressing concerns over share dilution and the stock's struggle to maintain gains.

Incannex Healthcare, Inc. is a biotech company, which engages in developing cannabinoid and psychedelic compound medicines. It focuses on the research and development for medicinal cannabis pharmaceutical products and psychedelic medicine therapies for treatment of a range of indications. The company was founded on April 27, 2001 and is headquartered in Norwest, Australia.

Incannex Healthcare Inc

Incannex Healthcare Limited - ADR

Incannex Healthcare (IXHL) is experiencing a notable rally driven by impending NASDAQ compliance and heightened speculation regarding positive FDA End-of-Phase 2 results for its Fast Track designated sleep apnea drug, IHL-42X, with its low share float further amplifying short squeeze potential among traders.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir Technologies is actively discussed following multiple strategic announcements, including a sovereign AI architecture with NVIDIA and expanded partnerships in defense, energy, and commercial AI. The community is highly enthusiastic, viewing these collaborations as strong validation of Palantir's AI platform and its crucial role across diverse, high-stakes sectors.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending after reporting a beat on earnings and achieving its first GAAP profitable year, complemented by a new $500M share buyback; however, its conservative forward guidance and subsequent analyst downgrades have fueled a community debate between bullish long-term conviction in agentic AI leadership and concerns over decelerating growth.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is trending after securing pivotal Japanese marketing approval for its Alpha DaRT technology, a massive de-risking event that has analysts raising price targets while the community asserts these valuations are still significantly undervalued given the company's strong cash position and promising oncology pipeline.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is trending due to a new development agreement with Tower Semiconductor to integrate its electro-optic polymer modulators into Tower's silicon photonics platform. The market views this as significant validation, fueling discussions about its role in future AI infrastructure and the long-term potential of its technology, despite ongoing volatility and profit-taking.

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. It offers Alpha, Beta, Gamma, and orbital transfer vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 27, 2017 and is headquartered in Cedar Park, TX.

Firefly Aerospace Inc.

Firefly Aerospace is trending following the successful launch of its Alpha Flight 7 mission, which delivered a Lockheed Martin payload into orbit, marking a crucial comeback for the Alpha rocket program and driving positive community sentiment in the competitive commercial space sector.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is trending due to escalating tanker attacks and critical supply disruptions in the Strait of Hormuz, driving strong community debate over whether substantial strategic reserve releases can mitigate the sustained geopolitical risk or if oil prices are poised for further significant volatility.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending as its community, fueled by strong conviction, relentlessly promotes the token's "OG Meme" status and authenticity as a Solana-based project, aiming for significant market cap expansion. The community emphasizes consistent engagement and 'bagworking' while encouraging others to join and avoid "fake" tokens.

Dollar General Corp. engages in the operation of merchandise stores. Its offerings include food, snacks, health and beauty aids, cleaning supplies, basic apparel, housewares, and seasonal items. It sells brands including Clorox, Energizer, Procter & Gamble, Hanes, Coca-Cola, Mars, Unilever, Nestle, Kimberly-Clark, Kellogg's, General Mills, and PepsiCo. The company was founded by J. L. Turner and Hurley Calister Turner Sr. in 1939 and is headquartered in Goodlettsville, TN.

Dollar General Corp.

Dollar General is trending following its robust earnings report, which surpassed expectations and included upbeat fiscal guidance and significant expansion plans. The community is split, with some questioning the immediate market reaction despite the strong results, while others highlight its appeal as a value-driven retailer benefiting from cautious consumer spending.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul><li>H.C. Wainwright stated that it “reshapes the regulatory calculus” for the company’s Huntington’s disease gene therapy, AMT-130.</li><li>The firm stated that it has “continued conviction” in AMT-130's existing dataset and uniQure's broader pipeline.</li><li>Analysts at Chardan nearly doubled their price target for uniQure to $31 from $16, while keeping a ‘Buy’ rating, citing Prasad’s departure for its optimism.</li></ul>uniQure NV stock continued to draw retail buzz after analysts at H.C. Wainwright noted on Tuesday that the shares are poised for a value inflection following the reported departure of a key U.S. Food and Drug Administration (FDA) official.According to TheFly, analysts at H.C. Wainwright reiterated their ‘Buy’ rating and a $70 price target for the stock, implying a potential upside of nearly 289% from Monday’s closing price.<a href="https://stocktwits.com/symbol/QURE">uniQure shares</a> were up nearly 7% in Tuesday’s pre-market trade after a 26% surge on Monday.<h2 class="st-heading-2">Why Is HC Wainwright Bullish?</h2>H.C. Wainwright stated that the departure of Vinay Prasad, the head of the FDA’s division of vaccines and gene therapies at the end of April, bodes well for uniQure, stating that it “reshapes the regulatory calculus” for the company’s Huntington’s disease gene therapy, AMT-130.H.C. Wainwright stated that it has “continued conviction” in AMT-130's existing dataset and uniQure's broader pipeline.Prasad is reportedly leaving the agency next month to return to academia.Analysts at Chardan nearly doubled their price target for uniQure to $31 from $16, while keeping a ‘Buy’ rating. The firm cited Prasad’s departure as the reason for its price target hike.Earlier this month, the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-qure-stock-almost-halve-pre-market-today/cZd344CRIcD">FDA&nbsp;</a>said it does not agree that uniQure’s Phase I/II data for AMT-130 are sufficient to serve as theprimary evidence of effectiveness for a marketing application for its Huntington’s disease gene therapy.“While we did not reach alignment on a submission pathway based on the Phase I/II data, we believe the totality and durability of our data warrant continued substantive dialogue regarding how the FDA’s stated commitment to regulatory flexibility may be appropriately applied in this setting,” said uniQure CEO Matt Kapusta.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits around uniQure trended in the ‘bullish’ territory at the time of writing.One user stated that this is the “gene therapy trade reset traders waited for.”<stembedurl>https://stocktwits.com/TradeThePool/message/647080386</stembedurl><a href="https://stocktwits.com/symbol/QURE">QURE stock</a> is down 25% year-to-date, but up 45% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bill-ackman-pershing-square-files-for-ipo-after-a-delay-of-more-than-a-year/cZdoYmJRIeU">Bill Ackman’s Pershing Square Files For IPO After A Delay Of More Than A Year</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the uniQure logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

QURE Stock’s Relentless Rally Continues Today — Here's Why HC Wainwright Is Bullish On uniQure

H.C. Wainwright stated that the reported departure of a key U.S. Food and Drug Administration official at the end of April bodes well for uniQure.

Equity

<ul class="summary-bullets"><li>UniQure’s AMT-130 is a gene therapy to reduce levels of the Huntingtin protein in the brain.</li><li>The FDA recently said that data from uniQure’s Phase I/II trials were not sufficient and recommended a new randomized Phase III study.</li><li>RBC Capital estimates a 50% chance of eventual approval as Prasad’s exit could reopen a more balanced discussion at the FDA about the risk-benefit profile of AMT-130.</li></ul>Shares of uniQure N.V. (QURE) surged more than 20% on Monday, following upgrades from Wall Street firms, citing a potentially improving regulatory outlook for its Huntington’s disease therapy.Wells Fargo upgraded the company to ‘Overweight’ from ‘Equal Weight’ and sharply raised its price target to $60 from $15, according to The Fly. This implies a 243% potential rise from its current price of around $17.5.<h2 class="st-heading-2">Vinay Prasad’s Reported Departure In Spotlight</h2>Wells Fargo said the outlook for uniQure’s experimental gene therapy AMT-130 could improve following reports that Vinay Prasad will leave the U.S. Food and Drug Administration (FDA) next month. Prasad, who serves as both the Chief Medical and Scientific Officer and the Director of the Center for Biologics Evaluation and Research at the FDA, is set to leave next month, according to a Bloomberg report on Friday.Wells Fargo also noted that strong criticism from the media and the Huntington’s disease community over the FDA’s call for a new Phase 3 trial highlights stakeholder support for the therapy. That backing could strengthen the drug’s chances during review, approval, and commercialization.AMT-130 is a gene therapy to reduce levels of the Huntingtin protein in the brain. It uses a virus to deliver genetic instructions that help lower the protein. The treatment is administered directly into the striatum, an area of the brain heavily affected by Huntington’s disease, through a surgical procedure.Separately, RBC Capital Markets upgraded uniQure to ‘Outperform’ from ‘Sector Perform’ and raised its price target to $35 from $11. The firm said Prasad’s exit could reopen a more balanced discussion at the FDA about the risk-benefit profile of AMT-130, estimating about a 50% chance of eventual approval.<h2 class="st-heading-2">FDA Seeks New Randomized Study</h2>The upgrades come after regulatory uncertainty weighed on the company earlier this year. The FDA recently said that data from uniQure’s Phase I/II trials were insufficient to support a marketing application and recommended that the company conduct a new randomized Phase III study, including a controversial sham surgery control group.uniQure has raised ethical concerns about such a trial design, arguing that it could expose patients to surgical risks without therapeutic benefit. The company plans to request another meeting with the FDA in the second quarter of 2026 to discuss potential study designs.Despite the regulatory debate, AMT-130 has shown promising early data. In an earlier study, patients receiving a high dose of the gene therapy experienced about a 75% slower rate of disease progression after three years, along with a slower decline in both motor function and cognitive ability.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the sharp rally, retail sentiment for <a href="https://stocktwits.com/symbol/QURE">QURE</a> on Stocktwits turned ‘bullish’ from ‘extremely bullish’ a day earlier, amid ‘extremely high’ message volumes.One user expects the stock to surge to $150 if the company receives the FDA approval.<stembedurl>https://stocktwits.com/ChineseTakeeout/message/646975511</stembedurl>Another user weighed the options present for short sellers and long-term investors.<stembedurl>https://stocktwits.com/sepsis74/message/646972082</stembedurl>The stock has declined nearly 28% so far in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/saudi-arabia-begins-slashing-oil-production-tpet-batl-indo-shares-continue-to-draw-retail-buzz/cZdVlsWRIIj">Saudi Arabia Begins Slashing Oil Production – TPET, BATL, INDO Stocks Continue To Draw Retail Buzz</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150

Wells Fargo upgraded uniQure’s stock to ‘Overweight,’ citing a bullish outlook for its gene therapy following reports that Vinay Prasad will leave the U.S. FDA next month.

<ul class="summary-bullets"><li>CorMedix’s Q4 revenue included $91.2 million from DefenCath sales and $37.4 million from the Melinta portfolio.</li><li>Total operating expenses for Q4 rose to $48.2 million, up 181% year-on-year.</li><li>CorMedix ended 2025 with $148.5 million in cash, cash equivalents, and short-term investments.</li></ul>CorMedix Inc. (CRMD) stock gained attention on Thursday, after the company announced its fourth-quarter (Q4) and full-year financial results for 2025, reporting a 312% year-on-year (YoY) jump in revenue.&nbsp;The company reported Q4 revenue of $128.6 million and an earnings per share (EPS) of $0.16. Though CorMedix’s revenue surpassed analysts’ consensus estimate of $127 million, EPS came in way below the estimated $0.82, according to Fiscal AI data.&nbsp;<h2 class="st-heading-2">What Are Stocktwits Users Saying?&nbsp;</h2><a href="https://stocktwits.com/symbol/CRMD">CorMedix stock</a> traded over 11% lower on Thursday morning. However, on Stocktwits, retail sentiment around the stock flipped to ‘bullish’ from ‘bearish’ territory the previous day. Message volume shifted to ‘high’ from ‘low’ in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_03_05_092009_png_aaa43e3104.webp" alt="CRMD’s Sentiment Meter and Message Volume as of 09:50 a.m. ET on Mar. 5, 2026 | Source: Stocktwits" width="930" height="102"><figcaption>CRMD’s Sentiment Meter and Message Volume as of 09:50 a.m. ET on Mar. 5, 2026 | Source: Stocktwits</figcaption></figure>A Stocktwits user said they are going long on the stock and hope to keep it until it climbs back to double digits.<stembedurl>https://stocktwits.com/JamesTiberius/message/646666139</stembedurl><h2 class="st-heading-2">Revenue Growth Driven by DefenCath and Melinta Acquisition</h2>CorMedix’s Q4 revenue included $91.2 million from DefenCath sales and $37.4 million from the Melinta portfolio. The Melinta revenue reflects the company’s first full quarter of contribution since its August 2025 acquisition.&nbsp;Total operating expenses for Q4 rose to $48.2 million, up 181% YoY. The expense increase primarily stems from the Melinta acquisition and includes $4.1 million in one-time costs, such as severance and integration expenses.&nbsp;<blockquote>“I am proud of the company’s progress over the past year as we have accelerated the expansion of patient access for DefenCath, completed our acquisition and integration of Melinta, and saw progress in our two ongoing Phase 3 clinical programs for Rezzayo prophylaxis and DefenCath in TPN.”-Joe Todisco, Chairman and CEO, CorMedix&nbsp;</blockquote>CorMedix ended 2025 with $148.5 million in cash, cash equivalents, and short-term investments, excluding restricted cash.CRMD stock has declined by over 37% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/help-stock-tanks-despite-strong-phase-2-results-for-anxiety-treatment-retail-buys-the-dip-ignoring-market-s-pessimism/cZdQHEpRI3O">HELP Stock Tanks 22% Despite Strong Phase 2 Results For Anxiety Treatment: Retail Buys The Dip Ignoring Market’s Pessimism</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the CorMedix logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Why Did CRMD Stock Tumble Over 11% Today?

The company reported mixed Q4 results with a revenue of $128.6 million and earnings per share of $0.16. 

<ul class="summary-bullets"><li>Results showed that BXCL501 helped reduce withdrawal symptoms and could be as effective as or better than lofexidine.</li><li>Patients receiving BXCL501 experienced more than a 30% reduction in withdrawal symptoms.</li><li>BioXcel said BXCL501 could also be well-suited for treating withdrawal from opioids adulterated with xylazine.</li></ul>Shares of BioXcel Therapeutics Inc (BTAI) gave up early gains to trade 5% higher on Thursday, after the company announced positive topline results from a Phase 2 trial evaluating BXCL501 for treating opioid withdrawal symptoms.Results of the study, which involved 80 patients, showed that BXCL501 helped reduce withdrawal symptoms and may be as effective as or better than lofexidine, an FDA-approved treatment for opioid withdrawal.&nbsp;<h2 class="st-heading-2">BXCL501 Treatment Shows 30% Reduction In Withdrawal Symptoms</h2>Patients receiving BXCL501 experienced more than a 30% reduction in withdrawal symptoms, with the strongest improvement seen on days three and four of treatment. The drug also showed a favorable safety and tolerability profile, with lower rates of certain cardiovascular side effects and no reports of sedation in the treatment groups.These findings build on the company’s earlier Phase 1b/2 RELEASE study, which established the tolerability of selected BXCL501 doses in opioid-dependent patients, and expand the results to a different clinical setting that included a methadone taper and an active comparator.BXCL501 could also be well-suited for treating withdrawal from opioids adulterated with xylazine, the company added.“Opioid withdrawal remains a significant burden on the healthcare system and patients, and despite available therapies, there is still a substantial unmet need for safe and more effective treatment options that can help patients successfully transition to other medications such as buprenorphine or naltrexone for long-term benefits,” said Sandra Comer, Principal Investigator of the study and Professor of Neurobiology in the Department of Psychiatry at Columbia University. &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/BTAI">BTAI</a> flipped to ‘extremely bullish’ from ‘neutral’ a day earlier, amid ‘extremely high’ message volumes.One user highlighted the company’s debt situation.<stembedurl>https://stocktwits.com/Just_An_Investor/message/646712839</stembedurl>Year-to-date, the stock has gained around 7%For updates and corrections, email newsroom[at]stocktwits[dot]com.

Tariff uncertainty has prompted several analysts to cut their price targets for Five9 stock. 

BTAI Stock Gained 5% Today - What's The Latest On Its Opioid Withdrawal Treatment? 

BioXcel announced positive Phase 2 results for evaluating treatment for opioid withdrawal symptoms.

BTAI Stock Gained 5% Today - What's The Latest On Its Opioid Withdrawal Treatment?

<ul class="summary-bullets"><li>The siRNA material will support the preclinical development of a therapeutic candidate for the treatment of a cardiovascular condition, the company said.</li><li>In January, Codexis tied up with Axolabs to evaluate its ECO Synthesis platform.</li><li>The firm is expected to post its Q4 results next week, with Wall Street expecting revenue to surge around 67% to $35.8 million.</li></ul>Shares of Codexis, Inc. (CDXS) gained 7% on Wednesday after the company announced an agreement with an innovator pharmaceutical company to manufacture 50 grams of small interfering RNA (siRNA) using its proprietary ECO Synthesis platform.Codexis, however, did not disclose the name of the firm.The siRNA material will support the preclinical development of a therapeutic candidate for the treatment of a cardiovascular condition. Codexis’ ECO Synthesis platform is built to enable scalable, high-fidelity production of complex siRNA therapies.As RNA-based medicines move beyond rare diseases into larger patient populations, manufacturing requirements are rising significantly. The company believes its enzymatic technology is well-positioned to meet this growing demand.&nbsp;“We are excited about this relationship as it represents an important entry point into what could become a high-volume opportunity,” said Alison Moore, President and Chief Executive Officer of Codexis.<h2 class="st-heading-2">Axolabs Partnership For ECO Synthesis Platform</h2>The news follows Codexis’ agreement earlier this year with Axolabs to evaluate its ECO Synthesis platform, a step that could lead to future licensing opportunities and wider adoption of the technology in RNA manufacturing.Kathleen Campau, Senior Director of Operations at Axolabs, had said that the technology could play a pivotal role in the future large-scale manufacturing of therapeutic oligonucleotides by enabling more sustainable and cost-effective production.The biotech firm is expected to post its fourth-quarter results next week, with Wall Street expecting revenue to surge around 67% to $35.8 million, according to Fiscal.ai data, while loss is expected to narrow to $0.04 per share.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/CDXS">CDXS</a> on Stocktwits turned ‘bullish’ from ‘neutral’ a day earlier, amid ‘high’ message volumes.One user believes the latest development adds “momentum and validation.”<stembedurl>https://stocktwits.com/Camille65/message/646560686</stembedurl>Another user noted they were neutral earlier but turned bullish on the stock after reading the announcement.<stembedurl>https://stocktwits.com/10xMoonstocks/message/646571515</stembedurl>The stock has been under heavy selling pressure this year, declining more than 36%Read also: &nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/crwv-stock-coreweave-perplexity-cloud-partnership/cZd9F11RI5u">CoreWeave Inks Deal With Perplexity – CRWV Stock Gains 6% Pre-Market, On Track To Arrest Post Earnings Slump</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Artistic representation of a trending chart.

Why Did CDXS Stock Jump 7% Today?

The company tied up with an innovator pharmaceutical company to manufacture 50 grams of small interfering RNA using a proprietary ECO Synthesis platform.

<ul class="summary-bullets"><li>Aardvark voluntarily paused the HERO Phase 3 trial on Friday after a routine safety monitoring of a healthy volunteer found reversible cardiac effects.</li><li>Aardvark said it no longer expects to release HERO trial topline data in Q3 2026.</li><li>Stifel called the development a “surprise” and said that the “added uncertainty is hard to get comfortable with.”</li></ul>Shares of Aardvark Therapeutics (AARD) plummeted 4% in pre-market trading on Monday after a wave of bearish analyst downgrades following the company’s decision to pause its Phase 3 trial evaluating the treatment for hyperphagia in patients with Prader-Willi syndrome.If the pre-market levels hold after the opening bell, <a href="https://stocktwits.com/symbol/AARD">AARD shares</a> could fall to their lowest levels since Apr. 9, 2025.On Friday, Aardvark said it voluntarily paused the HERO Phase 3 and related extension trials after a routine safety monitoring of a healthy volunteer found reversible cardiac effects at doses above the target therapeutic level.Aardvark said it no longer expects to release HERO trial topline data in the third quarter (Q3) of 2026 and will instead provide updated guidance in the second quarter.<h2 class="st-heading-2">Analyst Expresses Skepticism About The New Uncertainty</h2>Stifel downgraded Aardvark Therapeutics to ‘Hold’ from ‘Buy’ and reduced its price target to $6 from $24, according to The Fly. This represents a 52% downside to Friday’s closing price of $12.5. The brokerage called the development a “surprise” and said that the “added uncertainty is hard to get comfortable with.” It is “very hard to build confidence in what the path forward may look like,” Stifel added.Morgan Stanley downgraded Aardvark Therapeutics to ‘Equal Weight’ from ‘Overweight’ and significantly slashed its price target to $7 from $29, according to The Fly. While the brokerage still sees potential for ARD-101, it lowered its rating due to near-term uncertainties.RBC Capital said that timelines are likely to be significantly delayed as the Aardvark works with the FDA on next steps, adding a “layer of uncertainty” around the program. The brokerage downgraded the stock to ‘Sector Perform’ from ‘Outperform’ and cut its price target to $6 from $18.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>While retail sentiment on Stocktwits remained ‘extremely bullish,’ amid ‘extremely high’ message volumes, chatter was largely ‘bearish’.<img src="https://news.stocktwits-cdn.com/AARD_jpg_eaa4fec962.webp" alt="AARD.jpg">One user said the suspension of the trial was “one of the worst news.”<stembedurl>https://stocktwits.com/focafoca99/message/646219667</stembedurl>Another user expects the stock to decline to $3.<stembedurl>https://stocktwits.com/jojoraizza/message/646210388</stembedurl>The stock has lost around 56% so far in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/spy-falls-100-day-moving-average-oil-vix-middle-east-tensions/cZd33g2RIcH">SPY On Track To Fall Below 100-DMA For First Time In Nine Months – Retail Braces For Prolonged Volatility</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

S&P 500 Index trades listlessly ahead of Nvidia earnings. 

AARD Stock Slumps 54% Pre-Market – Here’s Why Analysts Are Not ‘Comfortable’ With The Suspension Of A Key Phase 3 Trial

Aardvark Therapeutics shares saw brokerage downgrades after the company paused its Phase 3 trial to treat hyperphagia in patients with Prader-Willi syndrome.

<ul class="summary-bullets"><li>Aurinia stated that the revenue from the sales of LUPKYNIS for the treatment of active lupus nephritis rose 29% YoY in Q4 to $74.2 million and 25% YoY for the full year to $271 million.</li><li>LUPKYNIS is the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, the company said.</li><li>Overall, LUPKYNIS sales accounted for about 96% of the company’s total revenue in Q4 and for the full year 2025.</li></ul>Aurinia Pharmaceuticals Inc. (AUPH) shares gained nearly 4% in Thursday’s pre-market trade after the company posted a fourth-quarter (Q4) earnings and revenue beat.Aurinia reported adjusted earnings per share (EPS) of $1.53 on revenue of $77.1 million, while Wall Street analysts expected an adjusted EPS of $0.22 on revenue of $74.7 million, according to Koyfin data.However, the company’s 2026 revenue guidance fell short of Wall Street expectations. Aurinia guided for revenue in the range of $315 million and $325 million during the year, but the consensus estimate stood at $326.8 million.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/AUPH">Aurinia Pharmaceuticals</a> trended in the ‘bullish’ territory, with message volumes at ‘high’ levels. The stock was among the top three trending tickers on the platform at the time of writing.<h2 class="st-heading-2">Active Lupus Nephritis Therapy Sales Gain Momentum</h2>Aurinia stated that the revenue from the sales of LUPKYNIS for the treatment of active lupus nephritis rose 29% YoY in Q4 to $74.2 million. For the full year, LUPKYNIS sales stood at $271 million, rising 25% YoY.LUPKYNIS is the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, the company said.Overall, LUPKYNIS sales contributed to about 96% of the company’s total revenue in Q4 as well as the full year 2025.Aurinia also stated that the full-year revenue includes a $10 million milestone payment received by the company following the approval of LUPKYNIS by regulators in Japan.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>One user called Aurinia’s earnings and cash position “solid.”<stembedurl>https://stocktwits.com/VSTN/message/645950955</stembedurl>Another user called Aurinia’s numbers “excellent,” saying they’re excited for the company's long-term shareholders.<stembedurl>https://stocktwits.com/Ballerdad1/message/645950749</stembedurl><a href="https://stocktwits.com/symbol/AUPH">AUPH stock</a> is down 10% year-to-date, but up 80% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/celh-stock-soaring-today-celsius-q4-earnings-beat/cZTG9gDRIb8">CELH Stock Is Soaring Pre-Market Today — What Is Driving The Surge?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Aurinia Pharmaceuticals logo is seen displayed on a smartphone screen

AUPH Stock Gains On Aurinia Pharma’s Q4 Beat, But 2026 Guidance Misses Estimates

Aurinia reported adjusted earnings per share of $1.53 on revenue of $77.1 million, while Wall Street analysts expected an adjusted EPS of $0.22 on revenue of $74.7 million, according to Koyfin data.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

<ul class="summary-bullets"><li>McCutcheon said findings presented for VIR-5500 surpassed expectations and strengthened Vir’s standing among therapies in prostate cancer.</li><li>He noted that the results bolster confidence in Vir’s PRO-XTEN platform and add support to the company’s outlook for its hepatitis D regimen.</li><li>Morgan Stanley analyst Michael Ulz increased his price target on Vir to $24 from $20.</li></ul>Vir Biotechnology Inc. (VIR) received a pair of bullish calls from Wall Street after unveiling fresh clinical data and a sizable new drug partnership, prompting analysts to raise their ratings and price targets on the stock.On Monday, the company reported strong fourth-quarter earnings and encouraging Phase 1 results for its cancer therapy study.&nbsp;<h2 class="st-heading-2">Raymond James Upgrades Vir Biotechnology</h2>Raymond James analyst Sean McCutcheon upgraded the stock to ‘Strong Buy’ from ‘Outperform’ and lifted his price target to $19 from $12 following the series of corporate updates, according to TheFly.&nbsp;According to McCutcheon, findings presented for VIR-5500 surpassed expectations and strengthened its standing among PSMA-directed T-cell engager therapies in prostate cancer.He noted that the results bolster confidence in Vir’s PRO-XTEN platform and add support to the company’s outlook for its hepatitis D regimen combining tobevibart and elebsiran, which he believes has a viable regulatory path.<a href="https://stocktwits.com/symbol/VIR">Vir Biotechnology stock</a> traded over 60% higher in Tuesday’s premarket. On Stocktwits, retail sentiment around the stock jumped to ‘extremely bullish’ from ‘neutral’ territory the previous day. Message volume shifted to ‘extremely high’ from ‘high’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_02_24_071715_png_bf610d177d.webp" alt="VIR’s Sentiment Meter and Message Volume as of 07:30 a.m. ET on Feb. 24, 2026 | Source: Stocktwits" width="926" height="103"><figcaption>VIR’s Sentiment Meter and Message Volume as of 07:30 a.m. ET on Feb. 24, 2026 | Source: Stocktwits</figcaption></figure>Separately, Morgan Stanley analyst Michael Ulz increased his price target on Vir to $24 from $20 while maintaining an ‘Overweight’ rating. Ulz said early-stage data for VIR-5500 reinforce its potential to emerge as a leading treatment option in prostate cancer.<h2 class="st-heading-2">New Partnership Adds Financial Backing</h2>Vir also announced a collaboration with Astellas Pharma that includes $335 million in upfront and near-term payments. The agreement outlines a 50/50 profit split in the U.S. and royalty payments on sales outside the country, providing additional capital and shared commercialization support.The partnership will co-develop and co-commercialize VIR-5500 through a sharing of expenses and revenues.&nbsp;Vir is eligible to earn up to $1.37 billion in additional development, regulatory, and sales milestones.VIR stock has declined by over 21% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apple-is-bringing-mac-mini-production-to-texas-now/cZRvveYR4zD">Apple Is Bringing Mac Mini Production To Texas Now</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Vir Biotechnology logo is seen on a smartphone and a computer screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnership

Raymond James analyst Sean McCutcheon upgraded the stock to ‘Strong Buy’ from ‘Outperform’ and lifted his price target to $19 from $12.

<ul class="summary-bullets"><li>Q4 net loss widened to $61.9 million from $59.2 million, primarily driven by higher R&amp;D expense.</li><li>R&amp;D expense for the quarter increased by $28.7 million to $63.9 million.</li><li>The company remains focused on completing enrollment in its BCG-naïve randomized trial and targeting a BLA filing by Q4 2026, CEO said.</li></ul>Shares of ImmunityBio, Inc. (IBRX) drew investor focus in pre-market trading on Monday after the pharmaceutical firm reported better-than-expected fourth-quarter results.The stock gained 11% with <a href="https://stocktwits.com/symbol/IBRX">IBRX</a> among the top trending tickers on Stocktwits at the time of writing.<h2 class="st-heading-2">ANKTIVA Boosts Q4 Revenue</h2>Net product revenue for Q4 surged 431% to $38.3 million, above Wall Street’s estimates of $37.8 million, according to Fiscal.ai data. ImmunityBio cited the increase in revenue to the sales of ANKTIVA, a U.S. Food and Drug Administration (FDA) approved immunotherapy for bladder and lung cancer.However, Q4 net loss widened to $61.9 million from $59.2 million, primarily driven by higher R&amp;D expense, the company said. R&amp;D expense for the quarter increased by $28.7 million to $63.9 million."As we advance toward initial international commercial activities, we remain focused on disciplined execution: completing enrollment in our BCG-naïve randomized trial with a BLA filing targeted by Q4&nbsp;2026, expanding the ANKTIVA label into lung cancer and lymphopenia, and converting our 700%&nbsp;revenue growth trajectory into durable, long-term value for shareholders," said Richard Adcock, President and CEO of ImmunityBio.<h2 class="st-heading-2">Anktiva Expansion Plans</h2>Earlier on Monday, Chairman Soon-Shiong <a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-open-week-on-high-chairman-teases-anktiva-3-year-expansion-plans-cancer-breakthrough/cZRtSeQR4Us/amp">said</a> on X that a detailed press release about a three-year expansion plan for the BioShield platform, including Anktiva, is expected to be released.&nbsp;He described it as a strong start to the year and discussed Anktiva’s IL-15 science, noting its importance in natural killer cell therapies. He added that IL-15 has long been viewed as a promising cancer-fighting cytokine and said Anktiva now uses it effectively.ImmunityBio has partnered with Biopharma and Cigalah Healthcare to launch Anktiva in Saudi Arabia and expand across the MENA region. The drug recently won approvals in Saudi Arabia and the European Union, bringing total approvals to 33 countries.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for IBRX on Stocktwits remained in the 'extremely bullish' zone, amid 'extremely high' message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/IBRX_jpg_a6c9147f3c.webp" alt="IBRX.jpg" width="934" height="109"><figcaption>IBRX's Sentiment Meter and Message Volumes on Feb. 24, 2026 | Source: Stocktwits</figcaption></figure>One user compared the stock to AAPL, stating that they were "adding aggressively."<stembedurl>https://stocktwits.com/BixbyKnolls/message/645637611</stembedurl>Another user expected a bigger rally.<stembedurl>https://stocktwits.com/Guitars7/message/645634938</stembedurl>Year-to-date, the stock has surged around 380%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tirx-stock-tian-ruixiang-rally-business-combination/cZRtvrnR4yl">This Nano-Cap Stock Shot Up 130% Today – What Triggered The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the ImmunityBio logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

ImmunityBio’s Q4 Revenue Gets A Lift From ANKTIVA Sales – IBRX Stock Gains 11%

Net product revenue in the fourth quarter surged 431% to $38.3 million, above estimates of $37.8 million, according to Fiscal.ai data

IBB
iShares Biotechnology ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IBB News

IBBiShares Biotechnology ETF